Skip to search formSkip to main contentSkip to account menu

filibuvir

Known as: (6R)-6-Cyclopentyl-6-(2-(2,6-Diethylpyridin-4-yl)Ethyl)-3-((5,7-Dimethyl(1,2,4)Triazolo(1,5- A)Pyrimidin-2-yl)Methyl)-4-Hydroxy-5,6-Dihydro-2H-Pyran-2-One, 2H-Pyran-2-One, 6-Cyclopentyl-6-(2-(2,6-Diethyl-4-Pyridinyl)Ethyl)-3-((5,7-Dimethyl(1,2,4)Triazolo(1,5-A)Pyrimidin-2-yl)Methyl)-5,6-Dihydro-4-Hydroxy-, (6R)- 
A non-nucleoside polymerase inhibitor of the hepatitis C virus NS5B RNA-dependent RNA polymerase. Filibuvir binds to the non-catalytic Thumb 2 site… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Since the outbreak of severe acute respiratory syndrome (SARS) in 2003, the harm caused by coronaviruses to the world cannot be… 
Highly Cited
2014
Highly Cited
2014
Hepatitis C virus (HCV) is a genetically diverse virus with multiple genotypes exhibiting remarkable differences, particularly in… 
2012
2012
ABSTRACT GS-9669 is a highly optimized thumb site II nonnucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase, with… 
Highly Cited
2011
Highly Cited
2011
ABSTRACT Filibuvir and VX-222 are nonnucleoside inhibitors (NNIs) that bind to the thumb II allosteric pocket of the hepatitis C… 
2011
2011
More effective and better‐tolerated therapies are needed for chronic hepatitis C virus (HCV) infection. Among the direct‐acting… 
2011
2011
ABSTRACT Filibuvir (PF-00868554) is an investigational nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural 5B… 
Review
2010
Review
2010
  • P. Beaulieu
  • IDrugs : the investigational drugs journal
  • 2010
  • Corpus ID: 23465083
Filibuvir (PF-868554), being developed by Pfizer, is an orally administered, non-nucleoside inhibitor of the HCV NS5B RNA…